{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:10:44Z","timestamp":1790172644193,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T00:00:00Z","timestamp":1551052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s10072-019-03764-z","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T14:53:26Z","timestamp":1551106406000},"page":"671-681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5204-7826","authenticated-orcid":false,"given":"Giuseppe","family":"Vita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olimpia","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,25]]},"reference":[{"key":"3764_CR1","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.tips.2018.09.001","volume":"39","author":"D Li","year":"2018","unstructured":"Li D, Mastaglia FL, Fletcher S, Wilton SD (2018) Precision medicine through antisense oligonucleotide-mediated exon skipping. Trends Pharmacol Sci 39:982\u2013994","journal-title":"Trends Pharmacol Sci"},{"key":"3764_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/WCO.0000000000000132","volume":"27","author":"R Quinlivan","year":"2014","unstructured":"Quinlivan R, Matthews E, Hanna MG (2014) Innovative care model for patients with complex muscle diseases. Curr Opin Neurol 27:607\u2013613","journal-title":"Curr Opin Neurol"},{"key":"3764_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, Cripe L, Herron AR, Kennedy A, Kinnett K, Naprawa J, Noritz G, Poysky J, Street N, Trout CJ, Weber DR, Ward LM, DMD Care Considerations Working Group (2018) Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 17:445\u2013455","journal-title":"Lancet Neurol"},{"key":"3764_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Qian Y, Sejersen T, SMA Care group (2018) Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord 28:197\u2013207","journal-title":"Neuromuscul Disord"},{"key":"3764_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S, Qian Y, Sejersen T, SMA Care Group (2018) Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 28:103\u2013115","journal-title":"Neuromuscul Disord"},{"key":"3764_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, March F, Vencesl\u00e1 A, Rodr\u00edguez-\u00c1lvarez FJ, Aller E, Fern\u00e1ndez RM, Borrego S, Mill\u00e1n JM, Hern\u00e1ndez-Chico C, Cusc\u00f3 I, Fuentes-Prior P, Tizzano EF (2018) Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord 28:208\u2013215","journal-title":"Neuromuscul Disord"},{"key":"3764_CR7","doi-asserted-by":"crossref","unstructured":"Messina S (2018) New directions for SMA therapy. J Clin Med 7(9)","DOI":"10.3390\/jcm7090251"},{"key":"3764_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","volume":"16","author":"E Bertini","year":"2017","unstructured":"Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, Lusakowska A, Comi GP, Cuisset JM, Abitbol JL, Scherrer B, Ducray PS, Buchbjerg J, Vianna E, van der Pol WL, Vuillerot C, Blaettler T, Fontoura P, Olesoxime SMA Phase 2 Study Investigators (2017) Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:513\u2013522","journal-title":"Lancet Neurol"},{"key":"3764_CR9","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC, ENDEAR Study Group (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723\u20131732","journal-title":"N Engl J Med"},{"key":"3764_CR10","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS, CHERISH Study Group (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625\u2013635","journal-title":"N Engl J Med"},{"key":"3764_CR11","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.nmd.2017.09.006","volume":"27","author":"S Messina","year":"2017","unstructured":"Messina S, Pane M, Sansone V, Bruno C, Catteruccia M, Vita G, Palermo C, Albamonte E, Pedemonte M, Bertini E, Binetti L, Mercuri E, Italian EAP working Group (2017) Expanded access program with nusinersen in SMA type I in Italy: strengths and pitfalls of a successful experience. Neuromuscul Disord 27:1084\u20131086","journal-title":"Neuromuscul Disord"},{"key":"3764_CR12","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.nmd.2018.05.010","volume":"28","author":"M Pane","year":"2018","unstructured":"Pane M, Palermo C, Messina S, Sansone VA, Bruno C, Catteruccia M, Sframeli M, Albamonte E, Pedemonte M, D\u2019Amico A, Brigati G, de Sanctis R, Coratti G, Lucibello S, Bertini E, Vita G, Tiziano FD, Mercuri E, Italian EAP working group (2018) Nusinersen in type 1 SMA infants, children and young adults: preliminary results on motor function. Neuromuscul Disord 28:582\u2013585","journal-title":"Neuromuscul Disord"},{"key":"3764_CR13","doi-asserted-by":"publisher","unstructured":"New warning of nusinersen-related communicating hydrocephalus (2018) Reactions Weekly 1714:3. https:\/\/doi.org\/10.1007\/s40278-018-50183-2","DOI":"10.1007\/s40278-018-50183-2"},{"key":"3764_CR14","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, Denk N, Feng Z, Green L, Guerard M, Jablonski P, Jacobsen B, Khwaja O, Kletzl H, Ko CP, Kustermann S, Marquet A, Metzger F, Mueller B, Naryshkin NA, Paushkin SV, Pinard E, Poirier A, Reutlinger M, Weetall M, Zeller A, Zhao X, Mueller L (2018) Discovery of risdiplam, a selective survival of motor neuron-2 ( SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem 61:6501\u20136517","journal-title":"J Med Chem"},{"key":"3764_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bcp.13786","volume":"85","author":"S Sturm","year":"2019","unstructured":"Sturm S, G\u00fcnther A, Jaber B, Jordan P, Al Kotbi N, Parkar N, Cleary Y, Frances N, Bergauer T, Heinig K, Kletzl H, Marquet A, Ratni H, Poirier A, M\u00fcller L, Czech C, Khwaja O (2019) A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol 85:181\u2013193","journal-title":"Br J Clin Pharmacol"},{"key":"3764_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/mt.2014.210","volume":"23","author":"K Meyer","year":"2015","unstructured":"Meyer K, Ferraiuolo L, Schmelzer L, Braun L, McGovern V, Likhite S, Michels O, Govoni A, Fitzgerald J, Morales P, Foust KD, Mendell JR, Burghes AH, Kaspar BK (2015) Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther 23:477\u2013487","journal-title":"Mol Ther"},{"key":"3764_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L'Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1713\u20131722","journal-title":"N Engl J Med"},{"key":"3764_CR18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","volume":"54","author":"S Al-Zaidy","year":"2019","unstructured":"Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, Church K, Lehman K, Sproule DM, Dabbous O, Maru B, Berry K, Arnold WD, Kissel JT, Mendell JR, Shell R (2019) Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol 54:179\u2013185","journal-title":"Pediatr Pulmonol"},{"key":"3764_CR19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.expneurol.2009.09.015","volume":"220","author":"S Messina","year":"2009","unstructured":"Messina S, Bitto A, Aguennouz M, Mazzeo A, Migliorato A, Polito F, Irrera N, Altavilla D, Vita GL, Russo M, Naro A, De Pasquale MG, Rizzuto E, Musar\u00f2 A, Squadrito F, Vita G (2009) Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone. Exp Neurol 220:349\u2013358","journal-title":"Exp Neurol"},{"key":"3764_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.nmd.2011.04.014","volume":"21","author":"S Messina","year":"2011","unstructured":"Messina S, Bitto A, Aguennouz M, Vita GL, Polito F, Irrera N, Altavilla D, Marini H, Migliorato A, Squadrito F, Vita G (2011) The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-\u03b1 activation and ameliorates muscle function and morphology in mdx mice. Neuromuscul Disord 21:579\u2013589","journal-title":"Neuromuscul Disord"},{"key":"3764_CR21","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/biof.1226","volume":"41","author":"S Messina","year":"2015","unstructured":"Messina S, Bitto A, Vita GL, Aguennouz M, Irrera N, Licata N, Sframeli M, Bruschetta D, Minutoli L, Altavilla D, Vita G, Squadrito F (2015) Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in mdx mice. BioFactors 41:324\u2013329","journal-title":"BioFactors"},{"issue":"10","key":"3764_CR22","doi-asserted-by":"publisher","first-page":"e0205514","DOI":"10.1371\/journal.pone.0205514","volume":"13","author":"GL Vita","year":"2018","unstructured":"Vita GL, Polito F, Oteri R, Arrigo R, Ciranni AM, Musumeci O, Messina S, Rodolico C, Di Giorgio RM, Vita G, Aguennouz M (2018) Hippo signaling pathway is altered in Duchenne muscular dystrophy. PLoS One 13(10):e0205514","journal-title":"PLoS One"},{"key":"3764_CR23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.nmd.2017.02.006","volume":"27","author":"A D'Amico","year":"2017","unstructured":"D'Amico A, Catteruccia M, Baranello G, Politano L, Govoni A, Previtali SC, Pane M, D'Angelo MG, Bruno C, Messina S, Ricci F, Pegoraro E, Pini A, Berardinelli A, Gorni K, Battini R, Vita G, Trucco F, Scutifero M, Petillo R, D\u2019Ambrosio P, Ardissone A, Pasanisi B, Vita G, Mongini T, Moggio M, Comi GP, Mercuri E, Bertini E (2017) Diagnosis of Duchenne muscular dystrophy in Italy in the last decade: critical issues and areas for improvements. Neuromuscul Disord 27:447\u2013451","journal-title":"Neuromuscul Disord"},{"key":"3764_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR, DMD Care Considerations Working Group (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17:251\u2013267","journal-title":"Lancet Neurol"},{"key":"3764_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, Sheehan DW, Bolen J, Weber DR, Ward LM, DMD Care Considerations Working Group (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17:347\u2013361","journal-title":"Lancet Neurol"},{"key":"3764_CR26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.nmd.2015.05.005","volume":"25","author":"J Rahbek","year":"2015","unstructured":"Rahbek J, Steffensen BF, Bushby K, de Groot IJ (2015) 206th ENMC international Workshop: care for a novel group of patients - adults with Duchenne muscular dystrophy. Naarden, The Netherlands, 23-25 May 2014. Neuromuscul Disord 25:727\u2013738","journal-title":"Neuromuscul Disord"},{"key":"3764_CR27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.4187\/respcare.00831","volume":"56","author":"JR Bach","year":"2011","unstructured":"Bach JR, Martinez D (2011) Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival. Respir Care 56:744\u2013750","journal-title":"Respir Care"},{"key":"3764_CR28","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s10072-018-3555-3","volume":"39","author":"S Messina","year":"2018","unstructured":"Messina S, Vita GL (2018) Clinical management of Duchenne muscular dystrophy: the state of the art. Neurol Sci 39:1837\u20131845. https:\/\/doi.org\/10.1007\/s10072-018-3555-3","journal-title":"Neurol Sci"},{"key":"3764_CR29","doi-asserted-by":"crossref","unstructured":"Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY (2016) Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev (5):CD003725","DOI":"10.1002\/14651858.CD003725.pub4"},{"key":"3764_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cct.2017.04.008","volume":"58","author":"M Guglieri","year":"2017","unstructured":"Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB, Herr BE, McColl E, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Willis T, Hirtz D, Shieh PB, Straub V, Childs AM, Ciafaloni E, Butterfield RJ, Horrocks I, Spinty S, Flanigan KM, Kuntz NL, Baranello G, Roper H, Morrison L, Mah JK, Manzur AY, McDonald CM, Schara U, von der Hagen M, Barohn RJ, Campbell C, Darras BT, Finkel RS, Vita G, Hughes I, Mongini T, Pegoraro E, Wicklund M, Wilichowski E, Bryan Burnette W, Howard JF, McMillan HJ, Thangarajh M, Griggs RC (2017) Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemp Clin Trials 58:34\u201339","journal-title":"Contemp Clin Trials"},{"key":"3764_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-7374-3_1","volume":"1687","author":"JK Mah","year":"2018","unstructured":"Mah JK (2018) An overview of recent therapeutics advances for Duchenne muscular dystrophy. Methods Mol Biol 1687:3\u201317","journal-title":"Methods Mol Biol"},{"key":"3764_CR32","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, Heydemann P, Kaminska A, Kirschner J, Muntoni F, Osorio AN, Schara U, Sejersen T, Shieh PB, Sweeney HL, Topaloglu H, Tulinius M, Vilchez JJ, Voit T, Wong B, Elfring G, Kroger H, Luo X, McIntosh J, Ong T, Riebling P, Souza M, Spiegel RJ, Peltz SW, Mercuri E, Clinical Evaluator Training Group, ACT DMD Study Group (2017) Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:1489\u20131498","journal-title":"Lancet"},{"key":"3764_CR33","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","volume":"25","author":"CA Stein","year":"2017","unstructured":"Stein CA, Castanotto D (2017) FDA-approved oligonucleotide therapies in 2017. Mol Ther 25:1069\u20131075","journal-title":"Mol Ther"},{"key":"3764_CR34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E, Eteplirsen Study Group and Telethon Foundation DMD Italian Network (2016) Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 79:257\u2013271","journal-title":"Ann Neurol"},{"key":"3764_CR35","doi-asserted-by":"crossref","unstructured":"Kinane TB, Mayer OH, Duda PW, Lowes LP, Moody SL, Mendell JR (2018) Long-term pulmonary function in Duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history. J Neuromuscul Dis 5:47\u201358","DOI":"10.3233\/JND-170272"},{"key":"3764_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/nat.2018.0756","volume":"29","author":"A Aartsma-Rus","year":"2019","unstructured":"Aartsma-Rus A, Goemans N (2019) A sequel to the eteplirsen saga: eteplirsen is approved in the United States but was not approved in Europe. Nucleic Acid Ther 29:13\u201315","journal-title":"Nucleic Acid Ther"},{"key":"3764_CR37","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nbt.3948","volume":"35","author":"N Iwamoto","year":"2017","unstructured":"Iwamoto N, Butler DCD, Svrzikapa N, Mohapatra S, Zlatev I, Sah DWY, Meena SSM, Lu G, Apponi LH, Frank-Kamenetsky M, Zhang JJ, Vargeese C, Verdine GL (2017) Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat Biotechnol 35:845\u2013851","journal-title":"Nat Biotechnol"},{"key":"3764_CR38","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.nmd.2018.06.009","volume":"28","author":"F Barth\u00e9l\u00e9my","year":"2018","unstructured":"Barth\u00e9l\u00e9my F, Wein N (2018) Personalized gene and cell therapy for Duchenne muscular dystrophy. Neuromuscul Disord 28:803\u2013824","journal-title":"Neuromuscul Disord"},{"key":"3764_CR39","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","volume":"26","author":"P Bettica","year":"2016","unstructured":"Bettica P, Petrini S, D'Oria V, D'Amico A, Catteruccia M, Pane M, Sivo S, Magri F, Brajkovic S, Messina S, Vita GL, Gatti B, Moggio M, Puri PL, Rocchetti M, De Nicolao G, Vita G, Comi GP, Bertini E, Mercuri E (2016) Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord 26:643\u2013649","journal-title":"Neuromuscul Disord"},{"key":"3764_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.steroids.2018.02.010","volume":"134","author":"EP Hoffman","year":"2018","unstructured":"Hoffman EP, Riddle V, Siegler MA, Dickerson D, Backonja M, Kramer WG, Nagaraju K, Gordish-Dressman H, Damsker JM, McCall JM (2018) Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids 134:43\u201352","journal-title":"Steroids"},{"key":"3764_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13052-017-0419-z","volume":"43","author":"D Cassandrini","year":"2017","unstructured":"Cassandrini D, Trovato R, Rubegni A, Lenzi S, Fiorillo C, Baldacci J, Minetti C, Astrea G, Bruno C, Santorelli FM, Italian Network on Congenital Myopathies (2017) Congenital myopathies: clinical phenotypes and new diagnostic tools. Ital J Pediatr 43:101","journal-title":"Ital J Pediatr"},{"key":"3764_CR42","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/mus.25658","volume":"56","author":"M Elverman","year":"2017","unstructured":"Elverman M, Goddard MA, Mack D, Snyder JM, Lawlor MW, Meng H, Beggs AH, Buj-Bello A, Poulard K, Marsh AP, Grange RW, Kelly VE, Childers MK (2017) Long-term effects of systemic gene therapy in a canine model of myotubular myopathy. Muscle Nerve 56:943\u2013953","journal-title":"Muscle Nerve"},{"issue":"Supp. 2","key":"3764_CR43","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.nmd.2018.06.240","volume":"28","author":"N Kuntz","year":"2018","unstructured":"Kuntz N, Shieh P, Smith B, B\u00f6nnemann C, Dowling J, Lawlor M, M\u00fcller-Felber W, Noursalehi M, Rico S, Servais L, Prasad S (2018) ASPIRO phase 1\/2 gene therapy trial in X-linked myotubular myopathy: preliminary safety and efficacy findings. Neuromuscul Disord 28(Supp. 2):S91","journal-title":"Neuromuscul Disord"},{"key":"3764_CR44","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1093\/brain\/awt133","volume":"136","author":"JR Trivedi","year":"2013","unstructured":"Trivedi JR, Bundy B, Statland J, Salajegheh M, Rayan DR, Venance SL, Wang Y, Fialho D, Matthews E, Cleland J, Gorham N, Herbelin L, Cannon S, Amato A, Griggs RC, Hanna MG, Barohn RJ, CINCH Consortium (2013) Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. Brain 136:2189\u20132200","journal-title":"Brain"},{"key":"3764_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/brain\/awp294","volume":"133","author":"E Matthews","year":"2010","unstructured":"Matthews E, Fialho D, Tan SV, Venance SL, Cannon SC, Sternberg D, Fontaine B, Amato AA, Barohn RJ, Griggs RC, Hanna MG, Investigators CINCH (2010) The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain 133:9\u201322","journal-title":"Brain"},{"key":"3764_CR46","doi-asserted-by":"publisher","first-page":"e20153289","DOI":"10.1542\/peds.2015-3289","volume":"137","author":"S Portaro","year":"2016","unstructured":"Portaro S, Rodolico C, Sinicropi S, Musumeci O, Valenzise M, Toscano A (2016) Flecainide-responsive myotonia permanens with SNEL onset: a new case and literature review. Pediatrics 137:e20153289","journal-title":"Pediatrics"},{"key":"3764_CR47","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/jnnp-2017-317615","volume":"89","author":"C Terracciano","year":"2018","unstructured":"Terracciano C, Farina O, Esposito T, Lombardi L, Napolitano F, Blasiis P, Ciccone G, Todisco V, Tuccillo F, Bernardini S, Di Iorio G, Melone MAB, Sampaolo S (2018) Successful long-term therapy with flecainide in a family with paramyotonia congenita. J Neurol Neurosurg Psychiatry 89:1232\u20131234","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3764_CR48","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1001\/jama.2012.12607","volume":"308","author":"J Statland","year":"2012","unstructured":"Statland J, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, Salajegheh MK, Venance SL, Ciafaloni E, Matthews E, Meola G, Herbelin L, Griggs RC, Barohn RJ, Hanna MG, Consortium for Clinical Investigation of Neurologic Channelopathies (2012) Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA 308:1357\u20131365","journal-title":"JAMA"},{"key":"3764_CR49","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/brain\/awx192","volume":"140","author":"G Andersen","year":"2017","unstructured":"Andersen G, Hedermann G, Witting N, Duno M, Andersen H, Vissing J (2017) The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Brain 140:2295\u20132305","journal-title":"Brain"},{"key":"3764_CR50","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1212\/WNL.0000000000004229","volume":"89","author":"WD Arnold","year":"2017","unstructured":"Arnold WD, Kline D, Sanderson A, Hawash AA, Bartlett A, Novak KR, Rich MM, Kissel JT (2017) Open-label trial of ranolazine for the treatment of myotonia congenita. Neurology 89:710\u2013713","journal-title":"Neurology"},{"key":"3764_CR51","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/mus.26372","volume":"59","author":"S Lorusso","year":"2019","unstructured":"Lorusso S, Kline D, Bartlett A, Freimer M, Agriesti J, Hawash AA, Rich MM, Kissel JT, David Arnold W (2019) Open-label trial of ranolazine for the treatment of paramyotonia congenita. Muscle Nerve 59:240\u2013243","journal-title":"Muscle Nerve"},{"key":"3764_CR52","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.neurol.2016.08.003","volume":"172","author":"M Antonio De","year":"2016","unstructured":"De Antonio M, Dogan C, Hamroun D, Mati M, Zerrouki S, Eymard B, Katsahian S, Bassez G, French Myotonic Dystrophy Clinical Network (2016) Unravelling the myotonic dystrophy type 1 clinical spectrum: a systematic registry-based study with implications for disease classification. Rev Neurol (Paris) 172:572\u2013580","journal-title":"Rev Neurol (Paris)"},{"key":"3764_CR53","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.omtn.2017.05.007","volume":"7","author":"D Jauvin","year":"2017","unstructured":"Jauvin D, Chr\u00e9tien J, Pandey SK, Martineau L, Revillod L, Bassez G, Lachon A, MacLeod AR, Gourdon G, Wheeler TM, Thornton CA, Bennett CF, Puymirat J (2017) Targeting DMPK with antisense oligonucleotide improves muscle strength in myotonic dystrophy type 1 mice. Mol Ther Nucleic Acids 7:465\u2013474","journal-title":"Mol Ther Nucleic Acids"},{"key":"3764_CR54","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1038\/mtna.2015.35","volume":"4","author":"D Laustriat","year":"2015","unstructured":"Laustriat D, Gide J, Barrault L, Chautard E, Benoit C, Auboeuf D, Boland A, Battail C, Artiguenave F, Deleuze JF, B\u00e9nit P, Rustin P, Franc S, Charpentier G, Furling D, Bassez G, Nissan X, Martinat C, Peschanski M, Baghdoyan S (2015) In vitro and in vivo modulation of alternative splicing by the biguanide metformin. Mol Ther Nucleic Acids 4:e262","journal-title":"Mol Ther Nucleic Acids"},{"key":"3764_CR55","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1093\/brain\/awy231","volume":"141","author":"G Bassez","year":"2018","unstructured":"Bassez G, Audureau E, Hogrel JY, Arrouasse R, Baghdoyan S, Bhugaloo H, Gourlay-Chu ML, Le Corvoisier P, Peschanski M (2018) Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial. Brain 141:2855\u20132865","journal-title":"Brain"},{"key":"3764_CR56","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT Ploeg Van der","year":"2008","unstructured":"Van der Ploeg AT, Reuser AJ (2008) Pompe\u2019s disease. Lancet 372:1342\u20131353","journal-title":"Lancet"},{"key":"3764_CR57","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","volume":"259","author":"C Angelini","year":"2012","unstructured":"Angelini C, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E, Moggio M, Filosto M, Sette E, Crescimanno G, Tonin P, Parini R, Morandi L, Marrosu G, Greco G, Musumeci O, Di Iorio G, Siciliano G, Donati MA, Carubbi F, Ermani M, Mongini T, Toscano A, Italian GSDII Group (2012) Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 259:952\u2013958","journal-title":"J Neurol"},{"key":"3764_CR58","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, Karamouzian M, Toscano A (2017) Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol 264:621\u2013630","journal-title":"J Neurol"},{"key":"3764_CR59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ymgme.2011.02.006","volume":"103","author":"DD Koeberl","year":"2011","unstructured":"Koeberl DD, Luo X, Sun B, McVie-Wylie A, Dai J, Li S, Banugaria SG, Chen YT, Bali DS (2011) Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol Genet Metab 103:107\u2013112","journal-title":"Mol Genet Metab"},{"key":"3764_CR60","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","volume":"288","author":"JA Maga","year":"2013","unstructured":"Maga JA, Zhou J, Kambampati R, Peng S, Wang X, Bohnsack RN, Thomm A, Golata S, Tom P, Dahms NM, Byrne BJ, LeBowitz JH (2013) Glycosylation independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in Pompe mice. J Biol Chem 288:1428\u20131438","journal-title":"J Biol Chem"},{"key":"3764_CR61","doi-asserted-by":"publisher","unstructured":"Pena LD, Barohn RJ, Byrne BJ, Desnuelle C, Goker-Alpan O, Ladha S, Lafor\u00eat P, Mengel KE, Pestronk A, Pouget J, Schoser B, Straub V, Trivedi J, Van Damme P, Vissing J, Young P, Kacena K, Shafi R, Thurberg BL, Culm-Merdek K, van der Ploeg AT, on behalf of the NEO1 Investigator Group (2018) Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-na\u00efve and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscul Disord. Dec 17. https:\/\/doi.org\/10.1016\/j.nmd.2018.12.004","DOI":"10.1016\/j.nmd.2018.12.004"},{"key":"3764_CR62","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.4155\/fmc.14.40","volume":"6","author":"G Parenti","year":"2014","unstructured":"Parenti G, Moracci M, Fecarotta S, Andria G (2014) Pharmacological chaperone therapy for lysosomal storage diseases. Future Med Chem 6:1031\u20131045","journal-title":"Future Med Chem"},{"key":"3764_CR63","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1038\/mt.2014.138","volume":"22","author":"G Parenti","year":"2014","unstructured":"Parenti G, Fecarotta S, la Marca G, Rossi B, Ascione S, Donati MA, Morandi LO, Ravaglia S, Pichiecchio A, Ombrone D, Sacchini M, Pasanisi MB, De Filippi P, Danesino C, Della Casa R, Romano A, Mollica C, Rosa M, Agovino T, Nusco E, Porto C, Andria G (2014) A chaperone enhances blood \u03b1-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. Mol Ther 22:2004\u20132012","journal-title":"Mol Ther"},{"key":"3764_CR64","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.expneurol.2016.07.013","volume":"287","author":"BK Smith","year":"2017","unstructured":"Smith BK, Martin AD, Lawson LA, Vernot V, Marcus J, Islam S, Shafi N, Corti M, Collins SW, Byrne BJ (2017) Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: clinical evidence of respiratory plasticity. Exp Neurol 287:216\u2013224","journal-title":"Exp Neurol"},{"key":"3764_CR65","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1089\/humc.2017.146","volume":"28","author":"M Corti","year":"2017","unstructured":"Corti M, Liberati C, Smith BK, Lawson LA, Tuna IS, Conlon TJ, Coleman KE, Islam S, Herzog RW, Fuller DD, Collins SW, Byrne BJ (2017) Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by Pompe disease. Hum Gene Ther Clin Dev 28:208\u2013218","journal-title":"Hum Gene Ther Clin Dev"},{"key":"3764_CR66","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","volume":"4","author":"SO Han","year":"2017","unstructured":"Han SO, Ronzitti G, Arnson B, Leborgne C, Li S, Mingozzi F, Koeberl D (2017) Low-dose liver-targeted gene therapy for Pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction. Mol Ther Methods Clin Dev 4:126\u2013136","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"418","key":"3764_CR67","doi-asserted-by":"publisher","first-page":"eaam6375","DOI":"10.1126\/scitranslmed.aam6375","volume":"9","author":"F Puzzo","year":"2017","unstructured":"Puzzo F, Colella P, Biferi MG, Bali D, Paulk NK, Vidal P, Collaud F, Simon-Sola M, Charles S, Hardet R, Leborgne C, Meliani A, Cohen-Tannoudji M, Astord S, Gjata B, Sellier P, van Wittenberghe L, Vignaud A, Boisgerault F, Barkats M, Laforet P, Kay MA, Koeberl DD, Ronzitti G, Mingozzi F (2017) Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase. Sci Transl Med 9(418):eaam6375","journal-title":"Sci Transl Med"},{"key":"3764_CR68","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/jmedgenet-2017-105012","volume":"55","author":"C Garone","year":"2018","unstructured":"Garone C, Taylor RW, Nascimento A, Poulton J, Fratter C, Dom\u00ednguez-Gonz\u00e1lez C, Evans JC, Loos M, Isohanni P, Suomalainen A, Ram D, Hughes MI, McFarland R, Barca E, Lopez Gomez C, Jayawant S, Thomas ND, Manzur AY, Kleinsteuber K, Martin MA, Kerr T, Gorman GS, Sommerville EW, Chinnery PF, Hofer M, Karch C, Ralph J, C\u00e1mara Y, Madruga-Garrido M, Dom\u00ednguez-Carral J, Ortez C, Emperador S, Montoya J, Chakrapani A, Kriger JF, Schoenaker R, Levin B, Thompson JLP, Long Y, Rahman S, Donati MA, DiMauro S, Hirano M (2018) Retrospective natural history of thymidine kinase 2 deficiency. J Med Genet 55:515\u2013521","journal-title":"J Med Genet"},{"key":"3764_CR69","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.15252\/emmm.201404092","volume":"6","author":"C Garone","year":"2014","unstructured":"Garone C, Garcia-Diaz B, Emmanuele V, Lopez LC, Tadesse S, Akman HO, Tanji K, Quinzii CM, Hirano M (2014) Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency. EMBO Mol Med 6:1016\u20131027","journal-title":"EMBO Mol Med"},{"key":"3764_CR70","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/ana.24922","volume":"81","author":"C Lopez-Gomez","year":"2017","unstructured":"Lopez-Gomez C, Levy RJ, Sanchez-Quintero MJ, Juanola-Falgarona M, Barca E, Garcia-Diaz B, Tadesse S, Garone C, Hirano M (2017) Deoxycytidine and deoxythymidine treatment for thymidine kinase 2 deficiency. Ann Neurol 81:641\u2013652","journal-title":"Ann Neurol"},{"key":"3764_CR71","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.nmd.2017.02.014","volume":"27","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Sejersen T, Mercuri E, ENMC SMA Workshop Study Group (2016) 218th ENMC International Workshop: Revisiting the consensus on standards of care in SMA. Naarden, The Netherlands, 19\u201321 February 2016. Neuromuscul Disord 27:596\u2013605","journal-title":"Neuromuscul Disord"},{"key":"3764_CR72","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.ejpn.2018.08.009","volume":"22","author":"EF Tizzano","year":"2018","unstructured":"Tizzano EF, Zafeiriou D (2018) Prenatal aspects in spinal muscular atrophy: from early detection to early presymptomatic intervention. Eur J Paediatr Neurol 22:944\u2013950","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"3764_CR73","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-016-0424-0","volume":"11","author":"C Klug","year":"2016","unstructured":"Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, Walter MC, Nagels KH (2016) Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis 11(1):58","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3764_CR74","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-017-0695-0","volume":"12","author":"J L\u00f3pez-Bastida","year":"2017","unstructured":"L\u00f3pez-Bastida J, Pe\u00f1a-Longobardo LM, Aranda-Reneo I, Tizzano E, Sefton M, Oliva-Moreno J (2017) Social\/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis 12(1):141","journal-title":"Orphanet J Rare Dis"},{"key":"3764_CR75","doi-asserted-by":"publisher","unstructured":"Zuluaga-Sanchez S, Teynor M, Knight C, Thompson R, Lundqvist T, Ekelund M, Forsmark A, Vickers AD, Lloyd A (2019) Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. Pharmacoeconomics Feb 4. https:\/\/doi.org\/10.1007\/s40273-019-00769-6","DOI":"10.1007\/s40273-019-00769-6"},{"key":"3764_CR76","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s10072-018-3506-z","volume":"39","author":"S Foresta La","year":"2018","unstructured":"La Foresta S, Faraone C, Sframeli M, Vita GL, Russo M, Profazio C, Rulli I, Gitto E, Versaci A, Messina S, Vita G (2018) Intrathecal administration of nusinersen in type 1 SMA: successful psychological program in a single Italian center. Neurol Sci 39:1961\u20131964","journal-title":"Neurol Sci"},{"key":"3764_CR77","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3233\/JND-180330","volume":"6","author":"M Pacione","year":"2019","unstructured":"Pacione M, Siskind CE, Day JW, Tabor HK (2019) Perspectives on Spinraza (nusinersen) treatment study: views of individuals and parents of children diagnosed with spinal muscular atrophy. J Neuromuscul Dis 6:119\u2013131","journal-title":"J Neuromuscul Dis"},{"key":"3764_CR78","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2016.10.014","volume":"25","author":"EL Agtmaal van","year":"2017","unstructured":"van Agtmaal EL, Andr\u00e9 LM, Willemse M, Cumming SA, van Kessel IDG, van den Broek WJAA, Gourdon G, Furling D, Mouly V, Monckton DG, Wansink DG, Wieringa B (2017) CRISPR\/Cas9-induced (CTG\u00b7CAG)n repeat instability in the myotonic dystrophy type 1 locus: implications for therapeutic genome editing. Mol Ther 25:24\u201343","journal-title":"Mol Ther"},{"key":"3764_CR79","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aau1549","volume":"362","author":"L Amoasii","year":"2018","unstructured":"Amoasii L, Hildyard JCW, Li H, Sanchez-Ortiz E, Mireault A, Caballero D, Harron R, Stathopoulou TR, Massey C, Shelton JM, Bassel-Duby R, Piercy RJ, Olson EN (2018) Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science 362:86\u201391","journal-title":"Science"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-019-03764-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-019-03764-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-019-03764-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T14:17:36Z","timestamp":1606573056000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-019-03764-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,25]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["3764"],"URL":"https:\/\/doi.org\/10.1007\/s10072-019-03764-z","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,25]]},"assertion":[{"value":"2 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G.V. discloses having been on advisory board for Avexis and Roche. He is also a principal investigator in clinical trials sponsored by Avexis, Roche, Sarepta, Santhera, Italfarmaco, Wave, and PTC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}